Regenerative pharmacology will have far higher development requirements. In fact, the challenges associated with regenerative pharmacology, i.e., curative therapeutics, will in many cases necessitate complex mixtures of compounds [i.e., growth factors such as fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet-derived growth factor, nerve growth factor (NGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), bone morphogenic proteins (BMPs These chemicals have far greater molecular weights (usually 10,000 to >100,000 mol. wt.) than those created historically by the pharmaceutical industry..